Allogene Therapeutics (ALLO)
2.05
+0.07 (3.54%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.
August 14, 2026 4:34 PM - SEC Filing
Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c
August 12, 2026 4:40 PM - StreetInsider
Allogene Therapeutics (ALLO) files $500M mixed shelf
August 12, 2026 4:30 PM - StreetInsider
Form S-3 Allogene Therapeutics,
August 12, 2026 4:23 PM - SEC Filing
Form 10-Q Allogene Therapeutics, For: Jun 30
August 12, 2026 4:18 PM - SEC Filing
Form 8-K Allogene Therapeutics, For: Aug 12
August 12, 2026 4:13 PM - SEC Filing
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie
August 7, 2026 8:21 PM - SEC Filing
Form SCHEDULE 13G Allogene Therapeutics, Filed by: STATE STREET CORP
August 7, 2026 8:33 AM - SEC Filing
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 4, 2026 8:30 AM - StreetInsider
FDA grants RMAT and fast track status to Allogene's cema-cel
July 29, 2026 8:32 AM - StreetInsider
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026 8:30 AM - StreetInsider
Allogene's CAR T therapy shows 31% response rate in kidney cancer
July 15, 2026 8:30 AM - StreetInsider
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Sol
July 15, 2026 8:30 AM - StreetInsider
Form 4 Allogene Therapeutics, For: Jul 01 Filed by: Roberts Zachary
July 6, 2026 5:51 PM - SEC Filing
Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Kazam Joshua A
June 23, 2026 4:35 PM - SEC Filing
Form 4 Allogene Therapeutics, For: Jun 18 Filed by: MESSEMER DEBORAH M.
June 23, 2026 4:34 PM - SEC Filing
Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Mayo Stephen
June 23, 2026 4:33 PM - SEC Filing
Form 4 Allogene Therapeutics, For: Jun 18 Filed by: SATO VICKI L
June 23, 2026 4:32 PM - SEC Filing
Form 4 Allogene Therapeutics, For: Jun 18 Filed by: WITTE OWEN N.
June 23, 2026 4:30 PM - SEC Filing
Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Humer Franz B
June 23, 2026 4:28 PM - SEC Filing
Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Barrett Elizabeth A.
June 23, 2026 4:27 PM - SEC Filing
Form 8-K Allogene Therapeutics, For: Jun 18
June 22, 2026 4:06 PM - SEC Filing
Form 424B5 Allogene Therapeutics,
June 22, 2026 4:04 PM - SEC Filing
Form DEFA14A Allogene Therapeutics,
May 28, 2026 5:51 PM - SEC Filing
Form 8-K Allogene Therapeutics, For: May 28
May 28, 2026 5:50 PM - SEC Filing
Allogene Therapeutics announces CEO succession plan
May 28, 2026 5:06 PM - StreetInsider
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026 5:02 PM - StreetInsider
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026 8:30 AM - StreetInsider
Form DEFA14A Allogene Therapeutics,
May 21, 2026 6:02 AM - SEC Filing
Full Article List
